Coronaviruses and their therapy
Identifieur interne : 004466 ( Main/Exploration ); précédent : 004465; suivant : 004467Coronaviruses and their therapy
Auteurs : Bart L. Haagmans [Pays-Bas] ; Albert D. M. E. Osterhaus [Pays-Bas]Source :
- Antiviral research [ 0166-3542 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Coronavirus (), Coronavirus (physiologie), Fusion membranaire (), Humains, Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Interférence par ARN, Interférons (pharmacologie), Protéines virales (), Réplication virale (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- pharmacologie : Interférons.
- physiologie : Coronavirus, Virus du SRAS.
- traitement médicamenteux : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- virologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Pascal (Inist)
English descriptors
- KwdEn :
- Animals, Antiviral, Coronavirus, Coronavirus (classification), Coronavirus (drug effects), Coronavirus (physiology), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Fusion inhibitor, Humans, Interferons (pharmacology), Membrane Fusion (drug effects), RNA Interference, Review, SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Severe acute respiratory syndrome, Treatment, Viral Proteins (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , drug effects : Viral Proteins.
- chemical , pharmacology : Interferons.
- classification : Coronavirus.
- drug effects : Coronavirus, Membrane Fusion, SARS Virus, Virus Replication.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- physiology : Coronavirus, SARS Virus.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Humans, RNA Interference.
Abstract
Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000451
- to stream PascalFrancis, to step Curation: 000539
- to stream PascalFrancis, to step Checkpoint: 000495
- to stream Main, to step Merge: 004696
- to stream Pmc, to step Corpus: 001685
- to stream Pmc, to step Curation: 001685
- to stream Pmc, to step Checkpoint: 001147
- to stream PubMed, to step Corpus: 002170
- to stream PubMed, to step Curation: 002170
- to stream PubMed, to step Checkpoint: 002244
- to stream Ncbi, to step Merge: 001572
- to stream Ncbi, to step Curation: 001572
- to stream Ncbi, to step Checkpoint: 001572
- to stream Main, to step Merge: 004142
- to stream Main, to step Curation: 004466
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0491674</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0491674 INIST</idno><idno type="RBID">Pascal:06-0491674</idno><idno type="wicri:Area/PascalFrancis/Corpus">000451</idno><idno type="wicri:Area/PascalFrancis/Curation">000539</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000495</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000495</idno><idno type="wicri:doubleKey">0166-3542:2006:Haagmans B:coronaviruses:and:their</idno><idno type="wicri:Area/Main/Merge">004696</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114240</idno><idno type="RBID">PMC:7114240</idno><idno type="wicri:Area/Pmc/Corpus">001685</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001685</idno><idno type="wicri:Area/Pmc/Curation">001685</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001685</idno><idno type="wicri:Area/Pmc/Checkpoint">001147</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001147</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16837072</idno><idno type="wicri:Area/PubMed/Corpus">002170</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002170</idno><idno type="wicri:Area/PubMed/Curation">002170</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002170</idno><idno type="wicri:Area/PubMed/Checkpoint">002244</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002244</idno><idno type="wicri:Area/Ncbi/Merge">001572</idno><idno type="wicri:Area/Ncbi/Curation">001572</idno><idno type="wicri:Area/Ncbi/Checkpoint">001572</idno><idno type="wicri:doubleKey">0166-3542:2006:Haagmans B:coronaviruses:and:their</idno><idno type="wicri:Area/Main/Merge">004142</idno><idno type="wicri:Area/Main/Curation">004466</idno><idno type="wicri:Area/Main/Exploration">004466</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral</term><term>Coronavirus</term><term>Coronavirus (classification)</term><term>Coronavirus (drug effects)</term><term>Coronavirus (physiology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Fusion inhibitor</term><term>Humans</term><term>Interferons (pharmacology)</term><term>Membrane Fusion (drug effects)</term><term>RNA Interference</term><term>Review</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severe acute respiratory syndrome</term><term>Treatment</term><term>Viral Proteins (drug effects)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Coronavirus ()</term><term>Coronavirus (physiologie)</term><term>Fusion membranaire ()</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Interférence par ARN</term><term>Interférons (pharmacologie)</term><term>Protéines virales ()</term><term>Réplication virale ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Interferons</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>Membrane Fusion</term><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Interférons</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>RNA Interference</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Coronavirus</term><term>Fusion membranaire</term><term>Humains</term><term>Interférence par ARN</term><term>Protéines virales</term><term>Réplication virale</term><term>Traitement</term><term>Article synthèse</term><term>Syndrome respiratoire aigu sévère</term><term>Antiviral</term><term>Coronavirus</term><term>Inhibiteur d'entrée</term><term>Virus du SRAS</term><term>inhibiteur de réplication</term><term>Inhibiteur de fusion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name></noRegion><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004466 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004466 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0491674
|texte= Coronaviruses and their therapy
}}
| This area was generated with Dilib version V0.6.33. |  |